A citation-based method for searching scientific literature

Howard Sofen, Stacy Smith, Robert T Matheson, Craig L Leonardi, Cesar Calderon, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J Marciniak, Yasmine Wasfi, Yuhua Wang, Philippe Szapary, James G Krueger. J Allergy Clin Immunol 2014
Times Cited: 190







List of co-cited articles
1314 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
205
40

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
39

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
285
34

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
33

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
32

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
James G Krueger, Laura K Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E L Wang, David Hall,[...]. J Allergy Clin Immunol 2015
167
32

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
276
32

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
182
30


Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
485
27

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
545
26

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
258
25

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
460
24

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Kim A Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B Russell, Elizabeth H Z Thompson,[...]. N Engl J Med 2012
711
20

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
618
19

Clinical improvement in psoriasis with specific targeting of interleukin-23.
Tamara Kopp, Elisabeth Riedl, Christine Bangert, Edward P Bowman, Elli Greisenegger, Ann Horowitz, Harald Kittler, Wendy M Blumenschein, Terrill K McClanahan, Thomas Marbury,[...]. Nature 2015
150
19

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli Zhuang, Cesar Calderon, Stanley J Marciniak, Esther Bouman-Thio, Philippe Szapary, Tong-Yuan Yang, Allen Schantz, Hugh M Davis, Honghui Zhou, Zhenhua Xu. Eur J Clin Pharmacol 2016
50
38

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
279
18

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
628
17

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
353
17

Psoriasis.
Frank O Nestle, Daniel H Kaplan, Jonathan Barker. N Engl J Med 2009
17

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
James G Krueger, Scott Fretzin, Mayte Suárez-Fariñas, Patrick A Haslett, Krista M Phipps, Gregory S Cameron, Juliet McColm, Artemis Katcherian, Inna Cueto, Traci White,[...]. J Allergy Clin Immunol 2012
254
17

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Craig Leonardi, Robert Matheson, Claus Zachariae, Gregory Cameron, Linda Li, Emily Edson-Heredia, Daniel Braun, Subhashis Banerjee. N Engl J Med 2012
703
16

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
B Oppmann, R Lesley, B Blom, J C Timans, Y Xu, B Hunte, F Vega, N Yu, J Wang, K Singh,[...]. Immunity 2000
16


The IL-23/Th17 axis in the immunopathogenesis of psoriasis.
Antonella Di Cesare, Paola Di Meglio, Frank O Nestle. J Invest Dermatol 2009
735
15

Immunology of psoriasis.
Michelle A Lowes, Mayte Suárez-Fariñas, James G Krueger. Annu Rev Immunol 2014
845
15

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
Edmund Lee, William L Trepicchio, Judith L Oestreicher, Debra Pittman, Frank Wang, Francesca Chamian, Madhav Dhodapkar, James G Krueger. J Exp Med 2004
659
15

Development, cytokine profile and function of human interleukin 17-producing helper T cells.
Nicholas J Wilson, Katia Boniface, Jason R Chan, Brent S McKenzie, Wendy M Blumenschein, Jeanine D Mattson, Beth Basham, Kathleen Smith, Taiying Chen, Franck Morel,[...]. Nat Immunol 2007
15

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
K A Papp, C E M Griffiths, K Gordon, M Lebwohl, P O Szapary, Y Wasfi, D Chan, M-C Hsu, V Ho, P D Ghislain,[...]. Br J Dermatol 2013
285
14


Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
14

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
190
14

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
800
13

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.
Yan Zheng, Dimitry M Danilenko, Patricia Valdez, Ian Kasman, Jeffrey Eastham-Anderson, Jianfeng Wu, Wenjun Ouyang. Nature 2007
13

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.
Claire L Langrish, Yi Chen, Wendy M Blumenschein, Jeanine Mattson, Beth Basham, Jonathan D Sedgwick, Terrill McClanahan, Robert A Kastelein, Daniel J Cua. J Exp Med 2005
13

IL-12 protects from psoriasiform skin inflammation.
Paulina Kulig, Stephanie Musiol, Sandra Nicole Freiberger, Bettina Schreiner, Gabor Gyülveszi, Giancarlo Russo, Stanislav Pantelyushin, Kenji Kishihara, Francesca Alessandrini, Thomas Kündig,[...]. Nat Commun 2016
105
13

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
K A Papp, S Tyring, M Lahfa, J Prinz, C E M Griffiths, A M Nakanishi, R Zitnik, P C M van de Kerkhof, Linda Melvin. Br J Dermatol 2005
525
12

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
Lisa C Zaba, Mayte Suárez-Fariñas, Judilyn Fuentes-Duculan, Kristine E Nograles, Emma Guttman-Yassky, Irma Cardinale, Michelle A Lowes, James G Krueger. J Allergy Clin Immunol 2009
236
12

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.
Andrea Chiricozzi, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Kristine E Nograles, Suyan Tian, Irma Cardinale, Sergio Chimenti, James G Krueger. J Invest Dermatol 2011
402
12

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.
Leslie van der Fits, Sabine Mourits, Jane S A Voerman, Marius Kant, Louis Boon, Jon D Laman, Ferry Cornelissen, Anne-Marie Mus, Edwin Florencia, Errol P Prens,[...]. J Immunol 2009
12

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Michele W L Teng, Edward P Bowman, Joshua J McElwee, Mark J Smyth, Jean-Laurent Casanova, Andrea M Cooper, Daniel J Cua. Nat Med 2015
451
12

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G Krueger, Richard G Langley, Craig Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T Dooley, Mark Lebwohl. N Engl J Med 2007
592
12

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
107
12

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.
Jason E Hawkes, Bernice Y Yan, Tom C Chan, James G Krueger. J Immunol 2018
209
12

Etanercept as monotherapy in patients with psoriasis.
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
883
11

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
A B Gottlieb, C Leonardi, F Kerdel, S Mehlis, M Olds, D A Williams. Br J Dermatol 2011
94
11

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
Kenneth B Gordon, Richard G Langley, Alice B Gottlieb, Kim A Papp, Gerald G Krueger, Bruce E Strober, David A Williams, Yihua Gu, Joaquin M Valdes. J Invest Dermatol 2012
122
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.